GILEAD SCIENCES SL
- Country
- 🇪🇸Spain
- Ownership
- -
- Established
- 1994-01-01
- Employees
- -
- Market Cap
- $95.8B
DORADO-AC - Optimized Doses of Darusentan as Compared to an Active Control in Resistant Hypertension
- Conditions
- Interventions
- First Posted Date
- 2006-10-19
- Last Posted Date
- 2014-03-18
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 849
- Registration Number
- NCT00389779
- Locations
- 🇺🇸
NEA Clinic, Jonesboro, Arkansas, United States
🇺🇸Cardiovascular Research Inst. of Dallas, Dallas, Texas, United States
🇺🇸Central Cardiology Medical Clinic, Bakersfield, California, United States
DORADO-AC-EX - A Long-Term Safety Extension Study to the Phase 3 DORADOC-AC Study (Protocol DAR-312) of Darusentan in Resistant Hypertension
- First Posted Date
- 2006-10-19
- Last Posted Date
- 2014-01-06
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 661
- Registration Number
- NCT00389675
- Locations
- 🇺🇸
Arkansas Primary Care Clinic, PA, Little Rock, Arkansas, United States
🇺🇸Medical Investigators, Inc., Little Rock, Arkansas, United States
🇺🇸St John's Center for Clinical Research, Jacksonville, Florida, United States
ProphyALL - Study on the Safety of Liposomal Amphotericin B to Prevent Antifungal Infections in Elderly Patients With Acute Lymphoblastic Leukemia
- Conditions
- First Posted Date
- 2006-10-12
- Last Posted Date
- 2007-08-21
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 20
- Registration Number
- NCT00386997
- Locations
- 🇩🇪
Gilead Sciences GmbH, Martinsried/Munich, Germany
Safety and Efficacy Study of Ambrisentan in Subjects With Pulmonary Hypertension
- First Posted Date
- 2006-09-25
- Last Posted Date
- 2012-04-05
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 224
- Registration Number
- NCT00380068
- Locations
- 🇺🇸
Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, California, United States
🇺🇸University of Chicago Hospitals, Chicago, Illinois, United States
🇺🇸Johns Hopkins University, Baltimore, Maryland, United States
Single Tablet Regimen (STR) Simplification Study for HIV-1 Infected Patients
- Conditions
- First Posted Date
- 2006-08-17
- Last Posted Date
- 2008-04-10
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 300
- Registration Number
- NCT00365612
A Clinical Study to Evaluate the Effects of Darusentan on Safety and Efficacy in Subjects With Resistant Systolic Hypertension Receiving Combination Therapy With Three or More Blood Pressure Lowering Drugs
- Conditions
- First Posted Date
- 2006-08-15
- Last Posted Date
- 2007-01-18
- Lead Sponsor
- Gilead Sciences
- Registration Number
- NCT00364026
GMB: Study of Truvada (TDF+FTC) or Emtricitabine (FTC) Alone Versus HAART Interruption in HIV-Infected Patients With Resistance
- Conditions
- Interventions
- First Posted Date
- 2006-08-10
- Last Posted Date
- 2009-03-31
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 50
- Registration Number
- NCT00362687
- Locations
- 🇪🇸
Gilead Sciences, S.L., Madrid, Spain
PROPHYSOME: Pilot Study on Safety of a Weekly Administration of 10mg/kg of AmBisome® in Antifungal Prophylaxis Treatment of Allogeneic Stem-cell Transplantation and Acute Leukaemia
- Conditions
- First Posted Date
- 2006-08-10
- Last Posted Date
- 2015-07-09
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 30
- Registration Number
- NCT00362544
- Locations
- 🇫🇷
Gilead Sciences, Paris, France
DORADO-EX: Long-Term Safety Extension Study to the Phase 3 DORADO Study (Protocol DAR-311) of Darusentan in Resistant Hypertension
- First Posted Date
- 2006-07-18
- Last Posted Date
- 2014-03-18
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 282
- Registration Number
- NCT00353574
- Locations
- 🇺🇸
Apex Research Institute, Santa Ana, California, United States
🇺🇸Cardiovascular Center of Sarasota, Sarasota, Florida, United States
🇺🇸Castlerock Clinical Research Consultants, Tulsa, Oklahoma, United States
Safety and Efficacy of Tenofovir DF in HIV-1 Infected Adolescents Failing Their Current Antiretroviral Therapy
- First Posted Date
- 2006-07-14
- Last Posted Date
- 2015-07-14
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 87
- Registration Number
- NCT00352053
- Locations
- 🇧🇷
Centro de Doenças Infecciosas e Parasitárias, Campo Grande - MS, Brazil
🇧🇷Hospital dos Servidores do Estado, Rio de Janeiro, Brazil
🇧🇷Faculdade de Medicina - UFMG, Belo Horizonte - MG, Brazil